Interview with Gabor Somlyai, Managing Director, HYD LLC.
You founded HYD almost 20 years ago, in 1992. Can you first explain to our readers why you made the switch from doing research at the Hungarian Institute of Oncology…
Founded in 1908, LEO Pharma is an independent, research-based pharmaceutical company.
LEO Pharma develops, manufactures and markets pharmaceutical drugs to dermatologic and thrombotic patients in more than 100 countries globally. To realise our vision of becoming the preferred dermatology care partner improving people’s lives around the world, we are expanding into new regions and markets, reaching more patients and societies with drugs and therapies that address unmet medical needs.
LEO Pharma has its own sales forces in 61 countries and employs around 5,000 employees worldwide and generates approximately USD 1.2 billion in annual turnover. The company is headquartered in Denmark and is wholly owned by the LEO Foundation.
2015 was the year LEO Pharma embarked on our ‘Helping SARAH – LEO towards 2020’ journey – a new strategy which was launched in December 2014. With the ambitious aspiration to help more than 100 million people in 2020, LEO Pharma has committed itself to looking at new and innovative solutions and keeping engaging in partnerships to reach its goal. LEO Pharma wants to offer solutions in all aspects of life for people living with skin diseases, to assist them in taking control of their condition and improve their quality of life. We have set out on a mission to help people achieve healthy skin; in addition to our products, we offer patients a growing list of solutions and services. As part of our 2020 strategy, we have established LEO Innovation Lab, a separate business unit operating independently outside our traditional business. LEO Innovation Lab works to improve the well-being of people living with psoriasis by developing digital solutions and services. Generic competition is today a market condition when running a pharmaceutical business with strong products and solutions, and 2015 was no exception. This year we upheld our patents for Daivobet® Ointment in court rulings in the UK and Canada. The result for 2015 is considered satisfactory
Contact
LEO Pharma A/S Hungarian Commercial Representative Office
Regus Obuda Gate
Arpad fejedelem utja 26-28., 5th floor
1023 Budapest
Hungary
Tel. (+36) 1 888 0525
You founded HYD almost 20 years ago, in 1992. Can you first explain to our readers why you made the switch from doing research at the Hungarian Institute of Oncology…
Hungary has been recognized as one of the largest pharmaceutical and healthcare markets in Central and Eastern Europe, and can obviously not be ignored by Roche. First of all, can…
You took over as GM back in 2008. No doubt that this was a challenging time to run a business, in particular in view of the external economic environment. Can…
The Hungarian pharmaceutical environment has been undergoing a turbulent time recently, with many new measures being implement by the Government. What are your observations, and how do you expect companies…
Assign Group started in 2002 as a small local CRO company founded in Austria; monitoring and doing minor project management only. Why was Austria chosen as the headquarters? First, it…
With approximately $90 billion flowing into the country (according to the Hungarian Investment and Trade Agency) since it abolished its centrally planned economy and transformed into an open, pro-business economy…
Taking a look at the voices of the pharmaceutical industry in Hungary, we see AIPM and MAYGOSZ as the 2 key associations. And while MAGYOSZ already represents many generic players……
IMS is a strong brand name when it comes to pharma and healthcare information worldwide. Can you please elaborate on the particularities that set the Hungarian pharmaceutical market apart from…
The Hungarian pharmaceutical environment has been undergoing many changes recently, such as a sales tax increase to 20%. Do you feel this is a climate of threat to MNCs in…
Hungary is one of the largest pharmaceutical markets in the region, and has been used by Janssen-Cilag as a hub. Can you elaborate on how important Hungary is for Janssen-Cilag…
Talking to Cegedim means talking to one of the experts in local market knowledge. Can you tell our readers from your point of view what really distinguishes Hungary from other…
Looking at Boehringer Ingelheim (BI) in Hungary, at first glance we see a company with a presence of already 20 years, which basically means an entry into this market right…
See our Cookie Privacy Policy Here
